Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LP
Launch One Acquisition Corp. Unit
LPAAU
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LP
LPAAU
LP
Launch One Acquisition Corp. Unit
LPAAU
News
·
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
Minovia Therapeutics announced the grant of two new U.S. patents (No. 12,502,408 and No. 12,329,781) covering its proprietary Mitochondrial Augmentation Therapy (MAT) platform for treating primary mitochondrial diseases and renal diseases. The patents, with corresponding grants in Europe and Japan, strengthen the company's intellectual property portfolio. Minovia's lead program MNV-201, currently in clinical trials for Pearson Syndrome, consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. The company is proceeding with a business combination with Launch One Acquisition Corp., expected to close in the first half of 2026.
Benzinga · Jan 13, 2026
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201, a novel cell therapy targeting Myelodysplastic Syndrome (MDS), and announced a planned business combination with Launch One Acquisition Corp.
Benzinga · Oct 15, 2025
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics received FDA Fast Track Designation for MNV-201, its investigational compound targeting Myelodysplastic Syndrome (MDS), potentially accelerating drug development and review process.
Benzinga · Sep 18, 2025
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
Minovia Therapeutics, a clinical-stage biotechnology company, and Launch One Acquisition Corp., a SPAC, have announced a proposed business combination to create a Nasdaq-listed mitochondrial therapy company focused on rare diseases and longevity.
Benzinga · Jun 25, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
LP
LPAAU
Launch One Acquisition Corp. Unit
Buy
Sell
Market
Limit
Soon
LPAAU
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any LPAAU yet.
Related Tickers
Earnings